CoChat

The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer

Open access
Schweizer, Michael T., Zhou, Xian C., Wang, Hao, Bassi, Sunakshi, Carducci, Michael A., Eisenberger, Mario A., Antonarakis, Emmanuel S. · 2014 · European Urology
Cited by 136

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background Taxanes may partly mediate their effect in castration-resistant prostate cancer (CRPC) through disruption of androgen-receptor trafficking along microtubules. This raises the possibility of cross-resistance between androgen-directed agents and docetaxel. Objective To evaluate docetaxel efficacy after abiraterone treatment in CRPC patients. Design, setting, and participants This was a single-institution, retrospective analysis in CRPC patients (N = 119) who either received abiraterone before docetaxel (AD) (n = 24) or did not receive abiraterone before docetaxel (docetaxel only; n = 95). Men initiated docetaxel between December 2007 (the date abiraterone was first used at our center) and May 2013. Outcome measurements and statistical analysis The primary efficacy end points were prostate-specific antigen (PSA) progression-free survival (PFS) and clinical/radiographic PFS on docetaxel. Differences between groups were assessed using univariate and multivariable analyses. Results and limitations Men in the AD group had a significantly higher risk for progression than those in the docetaxel-only group. Median PSA PFS was 4.1 mo in the AD group and 6.7 mo in the docetaxel-only group (p = 0.002). Median PFS was also shorter in the AD group (4.4 mo vs 7.6 mo; p = 0.003). In multivariable analysis, prior abiraterone treatment remained an independent predictor of shorter PSA PFS (hazard ratio [HR]: 3.48; 95% confidence interval [CI], 1.36–8.94; p = 0.01) and PFS (HR: 3.62; 95% CI, 1.41–9.27; p = 0.008). PSA declines ≥50% were less frequent in the AD group (38% vs 63%; p = 0.02). The small size and retrospective nature of this study may have introduced bias. Conclusions Men receiving abiraterone before docetaxel were more likely to progress on docetaxel and less likely to achieve a PSA response than abiraterone-naïve patients. Cross-resistance between abiraterone and docetaxel may explain these findings; however, larger, more definitive studies are still needed to confirm this.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2014.01.018

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 136

Metadata

Authors
Schweizer, M. T., Zhou, X. C., Wang, H., Bassi, S., Carducci, M. A., Eisenberger, M. A., & Antonarakis, E. S.
Venue
European Urology
Publisher
Elsevier BV
Published
2014-10
Volume
66
Issue
4
Pages
646-652
ISSN
0302-2838 (ISSN-L)
OpenAlex
W2116607127
Cited by
136
References
6
FWCI
19.87
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer. https://app.cochat.ai/papers/10.1016/j.eururo.2014.01.018
The paper
Schweizer, M. T., Zhou, X. C., Wang, H., Bassi, S., Carducci, M. A., Eisenberger, M. A., & Antonarakis, E. S. (2014). The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer. European Urology. https://doi.org/10.1016/j.eururo.2014.01.018

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.